NCT03954171Recruiting
Platino-resistance in Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 18 Nov 2025
Brief summary (registry, in English)
Prospective, monocentric study aiming to identify factors involved in platinum based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages). Patients will receive treatment (platinum based-chemotherapy) according to the standard practices. A prospective database and an associated biological collection will be performed during 5 years: * For each patient: clinical, biological, epidemiological and therapeutic treatment data will be collected during the standard therapeutic care. * Biological samples (blood samples, tumor biopsy specimens and ascites samples) will be collected for all patients. These samples will be collected at the same time as those taken in standard practice (no additional biopsy will be performed for the study). Study participation of each patient will be 5 years.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- First submitted
- 15 May 2019
- Start date
- 6 Mar 2020
- Primary completion date
- Mar 2033
- Lead sponsor
- Institut Claudius Regaud
- Diseases
- Ovarian cancer
- NCT number
- NCT03954171
What you commit to
- Study type: Interventional
- Planned participants: 600
- From 6 Mar 2020 to the primary completion date, Mar 2033
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with recurrent disease
- Exploratory surgery not performed at the "Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT-O)"
- Any psychological, familial, geographical or sociological condition potentially preventing the medical follow-up and/or study procedures
Other
- Non-epithelial ovarian tumor, borderline ovarian tumor
- Pregnant or breastfeeding women
- Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice)
Who the study is looking for
- Age ≥ 18 years old
- Epithelial ovarian cancer at initial diagnosis (all stages)
- Curative treatment (exeresis surgery) not yet initiated excepted neo-adjuvant treatment
- Indication of platinum based-chemotherapy
- Patient affiliated to the french social security system
- Patient must provide written informed consent prior to inclusion in the study and any study-specific procedure
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Universitaire du Cancer de Toulouse - Oncopole Coordinator of this site? Confirm its status | Toulouse | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.